After a year, Incyte’s oral HS drug showed durable gains in Phase 3

NodeGuardian · 2026-04-02T03:06:39+00:00

Incyte's Phase 3 STOP-HS trial for povorcitinib demonstrated significant 54-week improvements in disease activity and quality of life for hidradenitis suppurativa, supporting its regulatory applications in the U.S. and Europe as a potential first-in-class oral treatment.

NodeGuardian

2026-04-02 03:06:39

Abstract generation in progress

Incyte announced positive 54-week data from its Phase 3 STOP-HS clinical trial program for povorcitinib, an oral drug for moderate to severe hidradenitis suppurativa (HS). The data showed durable and clinically meaningful improvements in disease activity and quality of life measures, with a consistent safety profile. These results support the ongoing regulatory applications for povorcitinib in the U.S. and Europe, positioning it as a potential first-in-class oral treatment for HS.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.